Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 15/20 | 0.77 |
| ▸ | PIK3R1 | P27986 | 3/20 | 0.77 |
| ▸ | PIK3CD | O00329 | 14/20 | 0.69 |
| ▸ | PIK3CB | P42338 | 12/20 | 0.69 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.69 |
| ▸ | MTOR | P42345 | 4/20 | 0.66 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.60 |
| ▸ | PLK4 | O00444 | 1/20 | 0.60 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.60 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.60 |
| ▸ | GAK | O14976 | 1/20 | 0.60 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.60 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.60 |
| ▸ | STK16 | O75716 | 1/20 | 0.60 |
| ▸ | PIK3C2G | O75747 | 1/20 | 0.60 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.60 |
| ▸ | NQO2 | P16083 | 1/20 | 0.60 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.60 |
| ▸ | JAK1 | P23458 | 1/20 | 0.60 |
| ▸ | TYK2 | P29597 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2673635 | 0.89 | KDM4E (0.58) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1181724 | 0.88 | PIK3CA (0.81) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL13059937 | 0.87 | PIK3CA (0.81) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL189763 | 0.86 | PIK3CA (0.80) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL189597 | 0.84 | PIK3CA (0.66) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL190611 | 0.83 | PIK3CA (0.75) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL2672802 | 0.83 | PIK3CD (0.57) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL31323704 | 0.83 | PIK3CA (0.74) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL8216898 | 0.82 | PIK3CA (1.00) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG | |
| SCHEMBL1181083 | 0.81 | PIK3CA (0.79) | PIK3CAPIK3R1PIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9943519-B2 | Pharmaceutical compounds | GENENTECH, INC. (US) | 2018-04-17 | — | — | US | disclosed |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIRAMED LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| EP-2518074-B1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | HOFFMANN LA ROCHE (CH) | 2015-07-22 | — | — | EP | disclosed |
| US-8993563-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-10-16 | — | — | US | disclosed |
| US-8802670-B2 | Pharmaceutical compounds | F. HOFFMANN-LA ROCHE AG (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20130129820-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | GENENTECH, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-8383620-B2 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | GENENTECH, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2518074-A1 | Phosphoinositide 3-kinase inhibitor compounds and methods of use | F. Hoffmann-La Roche AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| EP-2402347-A1 | Pharmaceutical compounds | F. Hoffmann-La Roche AG (CH) | 2012-01-04 | — | — | EP | disclosed |
| WO-2007127175-A2 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-11-08 | — | — | WO | disclosed |
| US-7126015-B2 | Method for the preparation of hexahydro-furo-[2,3-b]furan-3-ol | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2006-10-24 | — | — | US | disclosed |
| US-20040249175-A1 | Method for the preparation of hexahydro-furo-[2,3-b]furan-3-ol | Janssen Sciences Ireland Unlimited Company (IE) | 2004-12-09 | — | — | US | disclosed |
| EP-1448567-A1 | METHOD FOR THE PREPARATION OF HEXAHYDRO-FURO 2,3-B]FURAN-3-OL | Tibotec Pharmaceuticals Ltd. (IE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003022853-A1 | METHOD FOR THE PREPARATION OF HEXAHYDRO-FURO[2,3-B]FURAN-3-OL | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2003-03-20 | — | — | WO | disclosed |
| US-6297410-B1 | 1-BROMO-2-CYCLOPROPYLETHYLENE WHICH MAY BE EFFICIENTLY DEHYDROHALOGENATED TO YIELD CYCLOPROPYLACETYLENE, THE CHEMICAL INTERMEDIATE FOR AN HIV REVERSE TRANSCRIPTASE INHIBITOR | DUPONT PHARMACEUTICALS COMPANY | 2001-10-02 | — | — | US | disclosed |
| US-6288297-B1 | REACTION OF ALDEHYDE WITH TRICHLOROACETIC ACID OR TRIBROMOACETIC ACID IN THE PRESENCE OF BASE CATALYST TO FORM HALOGENATED ALCOHOL, ETHERIFICATION IN THE PRESENCE OF COUPLING CATALYST AND ACID SCAVENGER | DUPONT PHARMACEUTICALS COMPANY | 2001-09-11 | — | — | US | disclosed |
| EP-1000001-A1 | A PROCESS FOR THE PREPARATION OF CYCLOPROPYLACETYLENE | Dupont Pharmaceuticals Company (US) | 2000-05-17 | — | — | EP | disclosed |
| US-6049019-A | Process for the preparation of cyclopropylacetylene | DUPONT PHARMACEUTICALS (US) | 2000-04-11 | — | — | US | disclosed |
| WO-1999006341-A1 | A PROCESS FOR THE PREPARATION OF CYCLOPROPYLACETYLENE | DUPONT PHARMACEUTICALS COMPANY (US) | 1999-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249175-A1 | Method for the preparation of hexahydro-furo-[2,3-b]furan-3-ol | HAAO, BBOX1, FBP1 | PIK3CA 3686/4885PIK3R1 4292/4885PIK3CD 3558/4885 |
| US-20140309216-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | PIK3CA 1/4885PIK3R1 19/4885PIK3CD 2/4885 |
| US-20130129820-A1 | PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE | PIK3CA, AKT3, PI4KA | PIK3CA 1/4885PIK3R1 16/4885PIK3CD 5/4885 |
| US-20160152632-A9 | PHARMACEUTICAL COMPOUNDS | PIK3CA, PIK3CD, AKT3 | PIK3CA 1/4885PIK3R1 19/4885PIK3CD 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.